Print  |  Close

A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement


Active: Yes
Cancer Type: Eye Cancer
Leukemia
NCT ID: NCT03011372
Trial Phases: Phase II Protocol IDs: INCB 54828-203 (primary)
NCI-2017-00141
Eligibility: 18 and over, Male and Female Study Type: Treatment
Study Sponsor: Incyte Corporation
NCI Full Details: http://clinicaltrials.gov/show/NCT03011372

Summary

The purpose of this study is to evaluate the efficacy and safety of INCB054828 in subjects

with myeloid/lymphoid neoplasms with fibroblast growth factor receptor (FGFR) 1

rearrangement.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.